Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma 450 million cell dose is the recommended dose for expansion (RDE); dose expansion to initiate by year end and data expected in 2026 92%